Natalizumab Risks and Benefits in Multiple Sclerosis

by alexperjescuadmin
in General Medicine
— 3 Mar, 2006

AudioMedica News

00:00 /

Chris Polman, Free University of Amsterdam
Abstract N Engl J Med 2006;345:899
Despite fears that natalizumab – which reduces progression in some categories of patients with multiple sclerosis – might increased the risk of a fatal viral infection, two-year randomised study finding have now given some reassurance that patients with relapsing disease can be treated.
[audio:https://www.audiomedica.com/podcasting/news/chris_polman.mp3]

Tags: disease natalizumab sclerosis viral